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Basilar artery occlusion (BAO) is a life-threatening condi-tion. Without treatment, a fatal outcome must be expected 
in >90% of patients.1,2 Even if treated, mortality rates of 30% 
to 40% have been reported.3,4 In view of these poor outcomes, 
treatment, if attempted, must not be delayed.5 Notably, ≈75% 
of the survivors have a favorable functional long-term out-
come with an acceptable quality of life.1
Symptoms of BAO include almost the entire spectrum of 
neurological deficits, such as altered consciousness, dysar-
thria, diplopia, dysphagia, ataxia, visual (field) disturbances, 
sensory deficits, and paresis.3 However, the main presenting 
and sometimes even only symptoms, especially in the early 
stage, can be vertigo or unspecific dizziness and unsteadi-
ness of stance and gait. The often subacute symptom onset, 
the varying time course, as well as the subtle, unspecific, and 
partly fluctuating symptoms in up to >90% of the patients can 
be challenging for the clinician and delay correct diagnosis.6
Depending on the clinical setting, nonenhanced com-
puted tomography (NECT) or transcranial Doppler and color-
coded duplex ultrasound (DUS) are used in the acute setting,7 
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especially if the pretest probability of BAO is relatively low. 
However, DUS of the basilar artery is uninterpretable in ≤50% 
of patients if standard noncontrast enhanced techniques are 
applied.8 In NECT, the hyperdense basilar artery sign alone 
has a low sensitivity ranging from 61% to 71%.9,10 Direct 
assessment using the more expensive computed tomographic 
angiography (CTA) or magnetic resonance (MR) angiography 
may thus be warranted in the acute setting, even if BAO is not 
likely because outcome crucially depends on prompt diagno-
sis and successful recanalization without delays.3,5
CTA and magnetic resonance imaging (MRI) (including 
standard nonenhanced, as well as angiographic sequences) 
are acknowledged as reference standard noninvasive imag-
ing modalities for BAO. Among these, CTA generally has a 
higher availability, faster acquisition time, and lower costs, 
but uses ionizing radiation and is especially associated with a 
greater risk of contrast medium-induced complications. This 
raises the question whether a more costly diagnostic technique 
such as MRI is justified in all patients even if the diagnosis of 
BAO is rather unlikely. Higher costs of CTA and MRI must 
be weighed against the risk of false-negative results leading to 
delayed diagnosis with NECT and DUS.
The aim of this study was to determine the cost effective-
ness of different imaging strategies using NECT, DUS, CTA, 
MRI, or combinations of these tests in patients with possible 
BAO.
Materials and Methods
Decision Model
We developed a decision model using decision-analytic software 
(TreeAge Pro 2014, version 14.1.1.0; TreeAge, Williamstown, 
MA) to evaluate the cost-effectiveness of different imaging strate-
gies for the diagnostic work-up of possible BAO in 63-year-old men3 
(Figure 1). We assessed NECT, CTA, and MRI separately, as well as 
duplex US combined with CTA or MRI. MRI for the exclusion of 
BAO both consists of unenhanced sequences to exclude an intracra-
nial hemorrhage, as well as time-of-flight MR angiography. In the 
combination strategies, CTA or MRI followed any abnormal duplex 
US result. Treatment was initiated if the test result of NECT, CTA, or 
MRI was positive. The time delay of treatment associated with each 
strategy, as well as other advantages and disadvantages were mod-
eled. Treatment was with IV thrombolysis or antithrombotics if there 
were contraindications for IV thrombolysis. The 1-month modified 
rankin Scale (mRS) score was used to measure short-term outcome. A 
Markov model with a 1-year cycle length was developed to estimate 
long-term outcomes and costs. Further details about the decision 
model are given in the online-only Data Supplement.
Data Sources and Input Parameters
The input data were based on the best available evidence in the lit-
erature. Clinical trial data and published clinical studies were used to 
estimate the input parameters (Tables 1 and 2; Table I in the online-
only Data Supplement.
Prior Probability
As BAO can present with an extremely broad spectrum of symptoms, 
the prior probability may vary significantly depending on the clinical 
symptoms at the time of presentation.6,10,11 We, therefore, assessed a 
broad range of prior probabilities in deterministic and probabilistic 
sensitivity analyses. Furthermore, as low prior probabilities are en-
countered mostly among patients with mild symptoms, we performed 
a subgroup analysis for this patient group, thereby also accounting 
for different outcomes among patients with different presentations. 
The corresponding input parameters for our model are presented in 
Table 1.
Diagnostic Test Performance
Data on the performance of NECT and DUS were derived from cross-
sectional studies that compared NECT9,10 and DUS8,11,27 to CTA as 
reference standard. Differences in the assessment of DUS originated 
from the application of contrast-enhanced techniques,11,27 which is 
still experimental and probably not readily available in the emergency 
department but promted us to perform extensive sensitivity analyses.
CTA and MR angiography are considered noninvasive standard 
tests with a sensitivity and specificity of close to 1.0.14–16 Further de-
tail about the diagnostic test performances is given in the online-only 
Data Supplement. The corresponding test performances that served 
as input parameters for our model are presented in Table 1.
Treatment Results
We modeled IV thrombolysis as treatment for BAO. As randomized 
trials on the optimal treatment of BAO treatment are still underway, 
there is currently no clear evidence for the superiority of endovas-
cular treatment for IV thrombolysis.3,28,29 Thus, we modeled only IV 
thrombolysis.
We derived the 1-month mRS outcomes for patients with 
BAO depending on the type of treatment performed from a study 
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Figure 1. Schematic model overview. ☐, decision 
node; ◯, chance node; M, Markov node; clone, the 
structure of the tree at that point is identical to the 
structure of a sub tree (marked with a thick black 
line and a corresponding number) but the input 
parameters are adjusted to apply to that specific 
situation. MRI+MR angiography (MRA) and NECT 
have a similar structure to computed tomographic 
angiography (CTA). DUS followed by MRI+MRA 
has a similar structure to DUS followed by CTA. 
*Delayed treatment follows after reimaging but has 
poorer long-term outcomes than immediate treat-
ment. BAO indicates basilar artery occlusion; DUS, 
duplex US; FN, false-negative; FP, false-positive; 
IV, intravenous; MRI, magnetic resonance imaging; 
NECT, nonenhanced CT; TN, true-negative; and TP, 
true-positive.
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Table 1. Summary of Input Parameters for the Decision Model With SE and Distribution Type, as well as References
Model Parameter Expected Value SE Distribution References
Age 63 ±10% Normal Schonewille et al3
Pretest probability 0.3 0.01–0.5 Uniform Estimated from the study by Goldmakher et al10 and 
Kermer et al11
Test performances
  NECT sensitivity 0.66 ±10% β Connell et al9 and Goldmakher et al10
  NECT specificity 0.85 ±10% β Connell et al9 and Goldmakher et al10
  DUS sensitivity 0.95 0.89–1.0 Triangular Brandt et al,8 Stolz et al,12 and Hoksbergen et al13
  DUS specificity 0.70 0.5–0.9 Triangular Brandt et al,8 Stolz et al,12 and Hoksbergen et al13
  CTA sensitivity 1.00 0.99–1.0 Triangular Ng et al14 and Bonatti et al15
  CTA specificity 1.00 0.99–1.0 Triangular Ng et al14 and Bonatti et al15
  MRI sensitivity 1.00 0.99–1.0 Triangular Wentz et al16
  MRI specificity 1.00 0.99–1.0 Triangular Wentz et al16
Outcome probabilities
  BAO, thrombolysis 0–3 h
   mRS, 0–2 0.29 ±20% β Schonewille et al3 and Vergouwen et al5
   mRS, 3–5 0.35 ±20% β Schonewille et al3 and Vergouwen et al5
   Death 0.36 ±20% β Schonewille et al3 and Vergouwen et al5
  BAO, thrombolysis 4–6 h
   mRS, 0–2 0.26 ±20% β Schonewille et al3 and Vergouwen et al5
   mRS, 3–5 0.36 ±20% β Schonewille et al3 and Vergouwen et al5
   Death 0.38 ±20% β Schonewille et al3 and Vergouwen et al5
  BAO, thrombolysis 7–9 h
   mRS, 0–2 0.11 ±20% β Schonewille et al3 and Vergouwen et al5
   mRS, 3–5 0.50 ±20% β Schonewille et al3 and Vergouwen et al5
   Death 0.39 ±20% β Schonewille et al3 and Vergouwen et al5
  BAO, thrombolysis >9 h
   mRS, 0–2 0.09 ±20% β Schonewille et al3 and Vergouwen et al5
   mRS, 3–5 0.45 ±20% β Schonewille et al3 and Vergouwen et al5
   Death 0.46 ±20% β Schonewille et al3 and Vergouwen et al5
  BAO, antithrombotics 0–3 h
   mRS, 0–2 0.35 ±20% β Schonewille et al3
   mRS, 3–5 0.38 ±20% β Schonewille et al3
   Death 0.27 ±20% β Schonewille et al3
  BAO, antithrombotics 4–6 h
   mRS, 0–2 0.31 ±20% β Schonewille et al3
   mRS, 3–5 0.39 ±20% β Schonewille et al3
   Death 0.30 ±20% β Schonewille et al3
  BAO, antithrombotics 7 to 9 h
   mRS, 0–2 0.14 ±20% β Schonewille et al3
   mRS, 3–5 0.56 ±20% β Schonewille et al3
   Death 0.30 ±20% β Schonewille et al3
  BAO, antithrombotics > 9 h
   mRS, 0–2 0.12 ±20% β Schonewille et al3
   mRS, 3–5 0.51 ±20% β Schonewille et al3
   Death 0.37 ±20% β Schonewille et al3
  No BAO
   Healthy 1 … … Assumption
   Death 0 … … Assumption
(Continued )
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by Vergouwen et al5 investigating the data of the Basilar Artery 
International Cooperation Study (BASICS), a large prospective reg-
istry study.3 These outcomes were similar to previously published 
90-days outcomes after IV thrombolysis4 but allowed a separate 
evaluation of patients receiving thrombolytic and patients receiving 
antithrombotic therapy as well as analysis of prognostic factors, such 
as time from symptom onset to treatment.
On the basis of a study by Katzan et al,22 we estimated that 5% 
of patients with BAO would have contraindications for thrombolytic 
therapy (ie, active gastro intestinal tract bleeding, uncontrolled hyper-
tension, oral anticoagulation with international normalized ratio >1.7, 
or recent brain injury). This number is considerably lower than the 
total number of ineligible patients in their study because (1) in BAO 
there is no clear time window for the administration of thrombolytic 
therapy and (2) contraindications, such as minor symptoms (National 
Institutes of Health Stroke Scale <4) and rapidly resolving symptoms 
would not apply for patients with BAO.
The BASICS study evaluated outcomes separately for patients 
with mild-to-moderate and severe symptoms.3 In our model, we per-
formed an overall analysis using the pooled data from these 2 groups, 
as well as a subgroup analysis for patients with mild symptoms. The 
corresponding input parameters for the overall analysis and for the 
subgroup analysis for patients with mild symptoms are presented in 
Table 1 and in Table I in the online-only Data Supplement, respectively.
Age- and sex-specific live tables were obtained for the US popu-
lation of 2007. The hazard rate ratios for the different health states 
(mRS, 0–5) were derived from the literature.17,20
Timing to Treatment
Time from symptom onset predicts the success of thrombolytic thera-
py in the anterior circulation30 and influences the treatment outcome in 
patients with BAO.5,31 Consequently, we modeled time from symptom 
onset as a factor determining the outcome after initiation of treatment. 
Detailed information is available in the online-only Data Supplement.
For each imaging strategy, a corresponding delay was added to 
the time from symptom onset. The respective input parameters are 
presented in Table 1.
Adverse Events
Information on the adverse events was obtained from the litera-
ture.21,23,32,33 We modeled contrast-induced nephropathy because of 
administration of contrast media during CTA21and risk of fatal radia-
tion-induced cancer because of CT scanning.23,32 The respective input 
parameters are given in Table 1. Detailed information is available in 
the online-only Data Supplement.
Health Benefit
Health benefits were measured using quality-adjusted life years 
(QALY). Lifetime QALYs were derived by multiplication of the num-
ber of years spent in each health state by the utility assigned to that 
health state. Utility weights range from 0.0 to 1.0, with 1.0 representing 
perfect health and 0.0 representing death. The utilities were obtained 
from 2 previously published studies,18,19 which have been used repeated-
ly in prior cost-effectiveness analyses.17,34 The utilities were calculated 
as averages weighted by the proportions of patients with the respective 
mRS outcome. The utility of a minor disability (mRS, 0–2) was 0.81 
and the utility of a major disability (mRS, 3–5) was 0.33. Death (mRS, 
6) was assigned a value of 0. The values are summarized in Table 1.
Costs
The model included costs for imaging with NECT, DUS, CTA, and 
MRI, complications from imaging, treatment with IV thrombolysis, 
and disability from BAO, including both short- and long-term care.
Timing data, min
  Time from symptom onset 312 ±240 γ Vergouwen et al5
  Perform and interpret NECT 10 5–15 Triangular Expert opinion
  Perform and interpret CTA 15 10–20 Triangular Expert opinion
  Perform and interpret MRI 45 20–60 Triangular Earnshaw et al17
  Perform and interpret DUS 30 20–50 Triangular Expert opinion
  Delay if false-negative 180 10–360 Uniform Expert opinion
Utility values
  Healthy 1 … … …
  mRS, 0–2 0.81 ±0.081 β Earnshaw et al,17 Stahl et al,18 and Gage et al19
  mRS, 3–5 0.33 ±0.033 β Earnshaw et al,17 Stahl et al,18 and Gage et al19
  Death 0 … … …
Death HRR
  mRS, 0–1 1.00 1.0–1.2 Triangular Earnshaw et al17 and Samsa et al20
  mRS, 2 1.11 1.0–1.2 Triangular Earnshaw et al17 and Samsa et al20
  mRS, 3 1.27 1.2–1.4 Triangular Earnshaw et al17 and Samsa et al20
  mRS, 4 1.71 1.3–2.0 Triangular Earnshaw et al17 and Samsa et al20
  mRS, 5 2.37 1.5–4.0 Triangular Earnshaw et al17 and Samsa et al20
Complication probabilities
  Contrast-induced nephropathy 0.005 0–0.02 Triangular Jackson et al21
  Contraindications for IV 
thrombolysis
0.05 ±20% β Katzan et al22
  Lifetime attributable risk of cancer 
after NECT scanning
0.0001 ±0.00001 Normal Holmes et al23
  Lifetime attributable risk of cancer 
after CTA scanning
0.0002 ±0.00002 Normal Holmes et al23
BAO indicates basilar artery occlusion; CTA, computed tomographic angiography; DUS, duplex ultrasound; HRR, hazard rate ratios; MRI, magnetic 
resonance imaging; mRs, modified rankin Scale; and NECT, nonenhanced computed tomography.
Table 1. Continued
Model Parameter Expected Value SE Distribution References
1844  Stroke  July 2015
Costs for imaging were based on the 2013 Medicare reimburse-
ment rates, including both technical and professional fees. Costs for 
complications from imaging have been described above. Costs for 
hospitalization have been reported in the literature.24 These costs 
included all costs incurred while in a hospital and total costs were 
obtained by stroke type and discharge status. The costs for treatment 
with IV thrombolysis were obtained from Earnshaw et al.17 Costs for 
IV thrombolysis included physician work and practice expense.
Annual post hospitalization costs have been repeatedly reported in 
the literature.17,24,35,36 These costs were obtained based on the patient’s 
health state. Death (mRS, 6) was assigned no annual post hospitaliza-
tion cost. All costs were converted into 2013 USD using the consumer 
price index for medical care. Benefits and costs were discounted at a 
rate of 3% per year as recommended for cost-effectiveness analyses 
in the United States.37 A summary of all costs used in this model is 
presented in Table 2.
Cost-Effectiveness and Sensitivity Analyses
Diagnostic strategies were compared in terms of costs, effectiveness 
(QALYs), incremental cost-effectiveness ratios, and net monetary 
benefit (NMB=QALY×willingness-to-pay [WTP]−costs), using a 
WTP threshold of $80 000 per QALY. NMB combines costs and ef-
fectiveness in 1 measure (NMB=(QALYs×WTP)−costs) with a high-
er NMB implying greater cost-effectiveness. QALYs and costs were 
calculated from the perspective of a healthcare payer.
We performed extensive sensitivity analyses to explore the ro-
bustness of the model’s assumptions. We used 1-way deterministic 
sensitivity analysis to identify variables with a significant influence 
on the model outcome. In addition, we performed 2- and 3-way sen-
sitivity analyses by altering the input values for 2 and 3 variables, 
respectively. A WTP threshold of $80,000 was used for these sensitiv-
ity analyses.
In addition to deterministic sensitivity analysis, we also per-
formed probabilistic sensitivity analyses, in which we altered the 
input values of all parameters simultaneously. Each parameter was 
assigned a distribution (β, triangular, or γ) and was varied according 
to this distribution. In addition, we calculated the probability of cost-
effectiveness for each strategy for varying WTP values using accept-
ability curves.
Results
Reference Case Analysis
In the reference-case analysis for male patients of 63 years 
old with possible BAO, CTA dominated all other strategies 
(Figure 2A). With a WTP threshold of $80 000 per QALY, 
CTA yielded the highest NMB, followed by MRI. The least 
cost-effective strategy was to perform NECT. In the refer-
ence-case analysis for patients with mild symptoms, CTA also 
dominated all other strategies (Figure 2C), albeit with smaller 
differences in QALYs and total costs compared with the over-
all analysis. A summary of the results is presented in Table 3. 
The results were similar for women (Table II; Figure I in the 
online-only Data Supplement).
Probabilistic Sensitivity Analysis
Results of the probabilistic sensitivity analysis showed that in 
men CTA was most cost effective in 96% of the simulation runs 
in the overall analysis and 80% of the mild symptoms analysis. 
DUS followed by CTA and DUS followed by MRI were the 
strategies of choice in only 2.6% and 0.07% of simulation runs 
Table 2. Costs in 2013 USD for Imaging, Complications From Imaging, Treatment and Disability 
From BAO, Including Both Short- and Long-Term Care
Model Parameter Expected Value SE Distribution References
Imaging
  NECT 167 ±16.7 γ Medicare 2013
  DUS 211 ±21.1 γ Medicare 2013
  CTA+NECT 424 ±42.4 γ Medicare 2013
  MRI+MRA 804 ±80.4 γ Medicare 2013
Treatment
  IV tPA 3829.55 ±382.96 γ Earnshaw et al17
  Administration of IV tPA 354.30 ±35.43 γ Earnshaw et al17
  Physician time to monitor IV tPA 
administration
711.97 ±71.20 γ Earnshaw et al17
Hospitalization
  Inpatient costs for patients with BAO 9809 4200–16 800 Triangular Young et al24
Post-hospitalization
  Annual post hospitalization costs for 
patients with mRS 0–2
8174 1–17 500 Triangular Young et al24
  Annual post hospitalization costs for 
patients with mRS, 3–5, first year
68 897 46 700–93 500 Triangular Young et al24
  Annual post hospitalization costs for 
patients with mRS 3–5, 2+ year
40 014 17 500–64 300 Triangular Young et al24
Complications
  Cost for contrast induced nephropathy 13 323 ±1332 γ Jackson et al21
  Cost for cancer 45 000 1–100 000 Triangular Estimated from23,25,26
BAO indicates basilar artery occlusion; CTA, computed tomographic angiography; DUS, duplex ultrasound; IV, intravenous; 
MRA, magnetic resonance angiography; MRI, magnetic resonance imaging; mRs, modified rankin Scale; NECT, nonenhanced 
computed tomography; and tPA, tissue-type plasminogen activator.
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in the overall analysis and 13% and 4.1% of simulation runs in 
the mild symptoms analysis, respectively. Those results were 
similar for women. The cost-effectiveness acceptability curves 
showing the most cost-effective strategy depending on the WTP 
threshold are given in Figure 2B and 2C for men and in Figure 
IB and IC in the online-only Data Supplement for women.
Deterministic Sensitivity Analyses
Prior Probability and Age
The model outcome was sensitive to varying the prior prob-
ability. With a WTP threshold of $80,000/QALY, CTA was 
more effective with an incremental cost-effectiveness ratio 
below the WTP threshold if the prior probability was >0.018 
for the overall analysis or >0.024 for patients with mild symp-
toms. With prior probabilities less than 0.018 and 0.024, DUS 
followed by CTA was more cost effective.
Model outcome was also influenced by the age of the 
patient. Varying age together with the prior probability in 
2-way sensitivity analyses showed that at a younger age <40 
years the MRI strategy was increasingly favored, whereas 
at age ≥80 years DUS followed by CTA was increasingly 
favored, at least in patients with a low prior probability. 
However, changes were minimal between the age of 45 and 
80 years—the age group, in which the vast majority of BAO 
cases occur (Figure II in the online-only Data Supplement).
DUS Sensitivity and Specificity
The choice between CTA and DUS followed by CTA was also 
affected by the sensitivity and specificity of DUS. Altering 
these 2 parameters together with the prior probability in 3-way 
sensitivity analyses showed that DUS followed by CTA would 
be cost-effective also at higher prior probabilities if sensitiv-
ity and specificity increased. However, even with perfect sen-
sitivity and specificity, the prior probabilities at which DUS 
followed by CTA was cost effective were low. Above a prior 
probability of ≈0.04 CTA was always the most cost-effective 
strategy (Figure 3 for men and Figure III in the online-only 
Data Supplement for women). In contrast, there was no 
change in cost-effectiveness if the sensitivity of CTA was var-
ied between 0.95 and 1.0 together with the prior probability. 
Varying the specificity of CTA between 0.95 and 1.0 resulted 
in slight changes of the cost-effectiveness between prior prob-
abilities of 0.02 and 0.03 for both analyses, favoring DUS 
followed by CTA also for higher probabilities if the specific-
ity of CTA decreased. Varying the sensitivity or specificity of 
MRI between 0.95 and 1.0 did not result in any changes of the 
model outcome.
Radiation Risk
Figure IV in the online-only Data Supplement shows the 
2-way sensitivity analyses exploring the influence of the 
lifetime attributable risk of cancer because of CT scanning. 
A B
C D
Figure 2. Cost-effectiveness graphs and acceptability curves in male patients. A and B, The results of the overall analysis. C and D,  
The results of the mild symptoms subgroup analysis. Cost-effectiveness graphs are shown in (A) and (C), acceptability curves are shown 
in (B) and (D). CTA is the optimal strategy in the overall analysis (A and B) and for patients with mild symptoms (C and D). CTA indicates 
computed tomographic angiography; DUS, duplex US; MRI, unenhanced magnetic resonance sequences+magnetic resonance angiogra-
phy; NECT, nonenhanced CT; and QALY, quality-adjusted life-year.
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Varying the lifetime attributable risk (LAR) after a single CT 
scan between 0 and 0.0003, the upper value corresponding to 
3× the estimated risk, resulted in a change of the most cost-
effective strategy between prior probabilities of 0.01 and 0.04, 
favoring DUS followed by CTA, as well as MRI as the LAR 
increased. Above a prior probability of 0.04, CTA was the 
most cost-effective strategy. There was only a marginal differ-
ence between the overall analysis and the analysis of patients 
with mild symptoms.
Timing to Treatment
Performing deterministic 2-way sensitivity analysis on the time 
to image and interpret MRI did not result in a change of the 
most cost-effective strategy at any prior probability in the over-
all analysis or in the analysis of patients with mild symptoms. 
Nor did performing sensitivity analysis on the time to image 
and interpret CTA result in a change of the most cost-effective 
strategy because both CTA as well as DUS followed by CTA 
were influenced by this analysis. Longer times to perform DUS 
resulted in changes of the most cost-effective strategy around 
a prior probability of 0.02, favoring direct CTA also in case 
of lower prior probabilities because the time to perform DUS 
increased (Figure V in the online-only Data Supplement).
Discussion
In our study on the cost-effectiveness of different noninva-
sive imaging tests for patients with possible BAO, we found 
direct CTA to be the most cost-effective strategy for a WTP 
threshold of $80 000/QALY. CTA yielded the most QALYs 
and although CTA was associated with higher initial imag-
ing costs, total costs were lower compared with other imag-
ing strategies as costs for long-term treatment were less. It, 
therefore, represented a dominant strategy. Cost-effectiveness 
acceptability curves showed that CTA remained cost-effective 
even for higher WTP thresholds.
Sensitivity analysis showed that DUS followed by CTA 
in case of a positive test result is cost effective for low prior 
probabilities. Depending on the sensitivity and specificity of 
DUS, the cut-off value of the prior probability below which 
DUS followed by CTA became the preferred strategy, var-
ied between 1% and 4%. Notably, even if perfect sensitiv-
ity and specificity were assumed, which would also require 
DUS to always yield interpretable results, CTA was still the 
most cost-effective strategy for prior probabilities above 
4%. Considering more realistic values for an acute setting, 
in which DUS may be uninterpretable in ≤50% when using 
noncontrast enhanced techniques,8 performing DUS because 
the initial test may only be cost-effective if the prior prob-
ability is <1%. These results remained nearly unchanged 
for females and for patients with mild symptoms at initial 
presentation.
Our results emphasize the paramount importance of a 
fast diagnostic work-up in BAO, also in relation to the cost 
of the imaging examination or potential risks, such as renal 
nephropathy or radiation-induced cancer. In our model, the 
delay was the key driver determining the most cost-effective 
strategy. It was the reason why performing DUS was only 
cost-effective at low prior probabilities—in combination 
with higher costs—why MRI never became the preferred 
strategy. Although there is no data available on the prior 
probability of BAO in patients only exhibiting mild symp-
toms to date, clinical experience indicates that the probabil-
ity may be ≥1%.
There are limitations of this study that need to be taken 
into account when interpreting the data. Because of limited 
evidence in the literature, several assumptions had to be made. 
First, as BAO is a rare disease, which can present with a vast 
variety of clinical symptoms,3,6 it is difficult to estimate the 
prior probability. This may question the generalizability of 
this model. Sensitivity analyses, however, showed that CTA 
remained cost-effective for most prior probabilities, whereas 
DUS became cost-effective only at low prior probabilities of 
around 1% to 2%. This indicates that CTA is cost-effective 
for many patients but implementation of the results of this 
study should be done cautiously for patients in whom BAO is 
unlikely. Our findings may thus work as a framework to help 
the physician in the initial decision-making process.
Second, the performance of imaging tests has only 
been described in studies with small numbers of patients.8,9 
Especially for DUS there is only limited data available. 
Sensitivity analysis, however, showed that the outcomes were 
robust to changes of these input parameters and that CTA was 
the most cost-effective strategy in the vast majority of scenar-
ios tested. The outcome between DUS and CTA was mainly 
driven by the effect of the time to perform and interpret test 
results and thus alterations of the values of test performance 
of DUS only resulted in slight changes in cost-effectiveness at 
prior probabilities between 1% and 4%.
Third, the predicted cancer risk associated with cranial 
CT scanning was derived from a study23 that used extrapola-
tion of risks of cancers found in a meta-analysis for pediat-
ric patients.38 In general, there is still uncertainty about the 
risk attributable to cranial CT scanning. Current estimates 
commonly use organ radiation doses and apply organ-spe-
cific cancer incidences, which are derived from studies of 
Table 3. Costs and Outcomes for Men
Total Costs 
(USD) QALYs ICER
NMB for WTP of $80 000/
QALY
Overall
  CTA 70 996 15.20 Dominant 1 144 992
  DUS+CTA 71 678 15.16 Dominated 1 141 130
  DUS+MRI 72 295 15.13 Dominated 1 138 455
  MRI 71 701 15.18 Dominated 1 142 496
  NECT 72 438 15.14 Dominated 1 138 415
Mild symptoms
  CTA 31 759 17.59 Dominant 1 375 338
  DUS+CTA 31 785 17.58 Dominated 1 374 339
  DUS+MRI 31 989 17.57 Dominated 1 374 484
  MRI 32 102 17.58 Dominated 1 374 498
  NECT 32 351 17.57 Dominated 1 373 187
CTA indicates computed tomographic angiography; ICER, incremental cost-
effectiveness ratio; MRI, magnetic resonance imaging; NECT, nonenhanced 
computed tomography; NMB, net monetary benefit; QALY, quality-adjusted life-
year; and WTP, willingness-to-pay.
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atomic-bomb survivors.39 The LAR of 0.0001 used in our 
study was derived from Holmes et al.23 who extrapolated 
the higher risks found for patients between the ages 0 and 
20 years by Stein et al.38 The estimates of Stein et al are in 
line with earlier reports.40 Nevertheless, there is still ambi-
guity about the LAR for adult patients we used in our study. 
However, sensitivity analyses showed that even an LAR 2× 
higher than the estimate only slightly influenced the model 
outcome, therefore, indicating only a minor role in the deci-
sion process for the diagnostic work-up of such a fatal dis-
ease, such as BAO.
Fourth, we only modeled IV thrombolysis as outcome, 
omitting potential intra-arterial treatment options. Therefore, 
we are not able to extrapolate the results to strategies guid-
ing those treatment options. The rationale was that this study 
intended to focus on the initial diagnostic imaging work-up 
by highlighting the influence of potential advantages and 
disadvantages associated with each of the different imaging 
strategies. Therefore, it was necessary to use the best evi-
dence on outcome estimates available to date. This is pro-
vided by the BASICS study.3 Because this study did not find 
any significant differences in the outcome between IV and 
IA thrombolysis, we limited the treatment in our model to 
IV therapy. It should be noted that our findings were robust, 
remaining nearly unchanged independent of whether out-
come estimates for all patients or for patients with mild 
symptoms were used, thereby indicating that better outcomes 
achieved with intra-arterial therapy may not change the deci-
sion of the initial imaging strategy. However, direct catheter 
angiography with the opportunity for an immediate inter-
vention may become cost-effective if the prior probability 
is high. Currently, a randomized controlled trial is being 
performed investigating the added value of IA therapy after 
IV therapy in patients with an acute symptomatic BAO.41 As 
soon as these data become available, our model can be easily 
adapted and updated.
Finally, the model assumed that CT, MRI, and DUS are 
available 24 hours a day, 7 days a week. Such an assump-
tion may only be valid for a stroke center and not for a 
small, rural hospital. However, as CT-based imaging is still 
the recommended standard for acute stroke work-up, CTA 
as the most cost-effective strategy in our model is likely to 
be available more readily than MRI or DUS. Furthermore, 
the model assumed that CT and MRI always yield interpre-
table results. This is in fact an oversimplified assumption 
because CT may be uninterpretable, for example, because 
of beam-hardening artifacts8 and MRI, for example, because 
of motion artifacts. We chose to refrain from modeling this 
because there is uncertainty about the risk of scans being 
uninterpretable. Sensitivity analyses, however, showed that 
results remained nearly unchanged even if CTA sensitivity 
and specificity were altered between 0.95 and 1.0, which 
may be used as an indicator of limited influence of uninter-
pretable test results.
A B
C D
Figure 3. Three-way sensitivity analyses exploring different sensitivities and specificities of duplex US (DUS) and different prior prob-
abilities with a willingness-to-pay of $80 000 per quality-adjusted life-year in men. A and B, The results of the overall analysis. C and D , 
The results of the mild symptoms subgroup analysis. Shading, optimal strategy. CTA indicates computed tomographic angiography; MRI, 
nonenhanced magnetic resonance sequences+magnetic resonance angiography; and NECT, nonenhanced CT.
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In conclusion, we demonstrated CTA to be cost-effective 
as the initial imaging test in many patients with possible BAO 
in an US American setting. When using standard noncontrast 
enhanced DUS techniques, DUS followed by CTA in case of 
an abnormal result is only cost-effective if the prior probabil-
ity is less than ≈1%. NECT and MRI are not cost-effective for 
this indication.
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